Haleon (HLN) Net Margin (2021 - 2023)

Haleon (HLN) posted Net Margin of 8.05% for Q4 2023, down 25.68% on a QoQ basis from 10.83% in Q2 2023, and down 2476.0% year-over-year from 0.34% in Q4 2022.

Haleon (HLN) Net Margin (2021 - 2023) Analysis & Trends

Haleon's Net Margin history runs 3 years deep, the most recent figure standing at 8.05% for Q4 2023.

  • Quarterly Net Margin fell 2476.0% year-over-year to 8.05% in Q4 2023, while the trailing twelve-month figure through Dec 2023 was 13.06% (changed N/A YoY) and the FY2025 annual result came in at 15.11%, up 228.0% from the prior year.
  • Net Margin was 8.05% for Q4 2023 at Haleon, down from 10.83% in the prior quarter.
  • Across five years, Net Margin topped out at 32.81% in Q4 2022 and bottomed at 8.05% in Q4 2023.
  • A 3-year average of 15.38% and a median of 12.2% in 2021 frame the typical range for Net Margin.
  • Annual changes were most pronounced in 2022 — Net Margin soared 2061 bps — and 2023, when it sank 2476 bps.
  • Haleon's Net Margin stood at 12.2% in 2021, then jumped by 169 bps to 32.81% in 2022, then tumbled by 75 bps to 8.05% in 2023.
  • Business Quant data shows HLN's Net Margin at 8.05% in Q4 2023, 10.83% in Q2 2023, and 13.03% in Q2 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Margin (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 9.29%
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn 26.57%
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn -33.66%
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn 35.18%
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn 5.03%
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn 24.30%
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn 4.16%
10 Vireo Growth 10.57 Bn 10.41 Bn 59.30 Mn -21.19%

Historic Data

Download Data
DateValue
Dec 31, 2023 8.05%
Jun 30, 2023 10.83%
May 3, 2023 13.03%
Dec 31, 2022 32.81%
Dec 31, 2021 12.20%